Join our daily newsletter At The Bell to receive exclusive market insights
- MGC Pharmaceuticals will begin a clinical trial comparing the efficacy of two of its epilepsy treatment drugs
- The clinical trial looks to identify the effect CBD has in treatments
- The two drugs to be tested is the low THC CannEpil and the 100 per cent CBD drug, MXP100
- MGC’s share price is up 2.56 per cent today, currently sitting at $0.040 apiece
MGC Pharmaceuticals has been given the go ahead to commence its clinical trial comparing its low THC epilepsy treatment to 100 per cent cannabidiol (CBD) products.
The study will compare the efficacy of CannEpil, the company’s low THC epilepsy drug, and MXP100, the company’s 100 per cent CBD treatment for epilepsy.
The Human Research Ethics Committee has approved the trial, which will be conducted in conjunction with Cannabis Access Clinics and Epilepsy Action Australia.
Co-founder and Managing Director of MGC Pharma Roby Zomer said the clinical trial hopes to prove the efficacy of CannEpil.
Designed for drug resistant epilepsy, the 20 to 1 ratio of CBD to THC in CannEpil will pinpoint the long term safety of THC. As well as, the efficacy of cannabinoid treatments in comparison to other available varieties and the long term impacts of cannabinoid medicines.
Dr Sanjay Nijahawan, the Medical Director at Cannabis Access Clinics said: “We hope studies like this will help doctors understand more about the clinical benefits of medicinal cannabis.”
A total of 100 patients will take place in the clinical trial, with 50 assigned CannEpil and 50 assigned MXP100. The trial take place over 12 months.
CEO of Epilepsy Action Australia Carol Ireland said the organisation encourages continued research into the effects cannabis treatments has on epilepsy, as it will “assist in ensuring it becomes mainstream”.
MGC’s share price is up 2.56 per cent today, currently sitting at $0.040 apiece, as of AEST 4:10 pm.
